GENERIC EQUIVALENTS - ISSUES AND CONCERNS

被引：27

作者：

LAMY, PP ^{[1
]}

机构：

[1] UNIV MARYLAND,SCH MED,BALTIMORE,MD 21201

来源：

关键词：

D O I：

10.1002/j.1552-4604.1986.tb03531.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：309 / 316

页数：8

共 46 条

[1] ABRAMS WB, 1985, DRUG INFORMATION J, V19, P395
[2] CRITICAL-EVALUATION OF THIORIDAZINE BIOEQUIVALENCE
BARONE, JA
COLAIZZI, JL
[J]. DRUG INTELLIGENCE & CLINICAL PHARMACY, 1985, 19 (11): : 847 - 858
[3] BLANCHARD J, 1979, PRINCIPLES PERSPECTI
[4] Cabana B E, 1983, Health Aff (Millwood), V2, P33, DOI 10.1377/hlthaff.2.3.33
[5] DADDARIO E, 1974, DRUG BIOEQUIVALENCE
[6] DANIELSON DA, 1985, GENERICS, V1, P21
[7] DEVAUGHGEISS J, 1985, CLIN THER, V7, P544
[8] GARRETT ER, 1985, INTEGRATED PSYCHIATR, V3, pS93
[9] GOTTSCHALK LA, 1985, INTEGRATIVE PSYCHIAT, V3, pS42
[10] HALPERIN JA, 1980, FED REGISTER, V45, P56832